Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 3
1953 1
1956 1
1959 1
1964 1
1980 8
1981 13
1982 28
1983 55
1984 77
1985 96
1986 114
1987 116
1988 80
1989 131
1990 158
1991 165
1992 159
1993 180
1994 176
1995 189
1996 201
1997 170
1998 163
1999 190
2000 165
2001 196
2002 211
2003 185
2004 258
2005 276
2006 215
2007 230
2008 209
2009 214
2010 220
2011 226
2012 211
2013 229
2014 201
2015 187
2016 180
2017 151
2018 182
2019 164
2020 153
2021 152
Text availability
Article attribute
Article type
Publication date

Search Results

6,460 results
Results by year
Filters applied: . Clear all
Page 1
Mitoxantrone, More than Just Another Topoisomerase II Poison.
Evison BJ, Sleebs BE, Watson KG, Phillips DR, Cutts SM. Evison BJ, et al. Med Res Rev. 2016 Mar;36(2):248-99. doi: 10.1002/med.21364. Epub 2015 Aug 19. Med Res Rev. 2016. PMID: 26286294 Review.
Mitoxantrone is a synthetic anthracenedione originally developed to improve the therapeutic profile of the anthracyclines and is commonly applied in the treatment of breast and prostate cancers, lymphomas, and leukemias. ...Here, we consider each of these interactions in t
Mitoxantrone is a synthetic anthracenedione originally developed to improve the therapeutic profile of the anthracyclines and is comm
[Mitoxantrone].
Pericot I, Montalban X. Pericot I, et al. Neurologia. 2003 Jul-Aug;18(6):318-23. Neurologia. 2003. PMID: 12838451 Review. Spanish.
Mitoxantrone is an antineoplastic agent that exerts a potent immunosuppresive effect, including suppression of B cell immunity and reduction of T cell numbers. ...In 2000, the FDA (Food and Drug Administration) approved the use of mitoxantrone for the treatment of a
Mitoxantrone is an antineoplastic agent that exerts a potent immunosuppresive effect, including suppression of B cell immunity and re
A case of mitoxantrone extravasation.
Chang A. Chang A. J Oncol Pharm Pract. 2020 Jul;26(5):1270-1273. doi: 10.1177/1078155219893736. Epub 2020 Jan 6. J Oncol Pharm Pract. 2020. PMID: 31902285
The literature has been conflicting in classifying mitoxantrone as a vesicant or irritant. CASE REPORT: We report a patient who had an extravasation of mitoxantrone. Mitoxantrone was administered in 50 ml normal saline. After mitoxantrone was completel …
The literature has been conflicting in classifying mitoxantrone as a vesicant or irritant. CASE REPORT: We report a patient who had a …
Mitoxantrone-Surfactant Interactions: A Physicochemical Overview.
Enache M, Toader AM, Enache MI. Enache M, et al. Molecules. 2016 Oct 13;21(10):1356. doi: 10.3390/molecules21101356. Molecules. 2016. PMID: 27754390 Free PMC article. Review.
Mitoxantrone is a synthetic anticancer drug used clinically in the treatment of different types of cancer. ...The present review describes the physicochemical aspects of the interactions between the anticancer drug mitoxantrone and different surfactants. Mitoxant
Mitoxantrone is a synthetic anticancer drug used clinically in the treatment of different types of cancer. ...The present review desc
Mitoxantrone for multiple sclerosis.
Martinelli Boneschi F, Rovaris M, Capra R, Comi G. Martinelli Boneschi F, et al. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD002127. doi: 10.1002/14651858.CD002127.pub2. Cochrane Database Syst Rev. 2005. PMID: 16235298 Updated. Review.
BACKGROUND: Mitoxantrone (MX) has been shown to be moderately effective in reducing the clinical outcome measures of disease activity in multiple sclerosis (MS) patients. ...
BACKGROUND: Mitoxantrone (MX) has been shown to be moderately effective in reducing the clinical outcome measures of disease activity …
Mitoxantrone treatment of multiple sclerosis: safety considerations.
Cohen BA, Mikol DD. Cohen BA, et al. Neurology. 2004 Dec 28;63(12 Suppl 6):S28-32. doi: 10.1212/wnl.63.12_suppl_6.s28. Neurology. 2004. PMID: 15623667 Review.
Treatment of patients with mitoxantrone for worsening multiple sclerosis (MS) requires careful monitoring for possible adverse events. ...Studies under way address whether concomitant administration of dexrazoxane with mitoxantrone might decrease the risk for cardia …
Treatment of patients with mitoxantrone for worsening multiple sclerosis (MS) requires careful monitoring for possible adverse events …
Mitoxantrone immunotherapy in multiple sclerosis.
Gonsette RE. Gonsette RE. Mult Scler. 1996 Jul;1(6):329-32. doi: 10.1177/135245859600100608. Mult Scler. 1996. PMID: 9345411 Review.
Mitoxantrone, a cytotoxic agent recently developed, was subsequently found a very potent immunosuppressor. ...Given its major immunosuppressive activity and its better tolerance, mitoxantrone was a potential candidate for multiple sclerosis therapy. ...
Mitoxantrone, a cytotoxic agent recently developed, was subsequently found a very potent immunosuppressor. ...Given its major immunos
Is there a new place for mitoxantrone in the treatment of multiple sclerosis?
Wawrzyniak S, Rzepiński Ł. Wawrzyniak S, et al. Neurol Neurochir Pol. 2020;54(1):54-61. doi: 10.5603/PJNNS.a2019.0069. Epub 2020 Jan 10. Neurol Neurochir Pol. 2020. PMID: 31922582 Free article.
AIM OF THE STUDY: To compare the clinical and neuroradiological efficacy of mitoxantrone (MTX) in various forms of multiple sclerosis (MS), to ascertain whether there is a new place for the drug in the treatment regimen of the disease, as well as to determine its safety pr …
AIM OF THE STUDY: To compare the clinical and neuroradiological efficacy of mitoxantrone (MTX) in various forms of multiple sclerosis …
[Mitoxantrone - an anthraquinone antibiotic with antitumor activity applied for the treatment of multiple sclerosis].
Szwed M. Szwed M. Postepy Hig Med Dosw (Online). 2014 Feb 21;68:198-208. doi: 10.5604/17322693.1091102. Postepy Hig Med Dosw (Online). 2014. PMID: 24662788 Free article. Review. Polish.
Mitoxantrone is an antineoplastic agent approved for clinical use in the secondary progressive phase of multiple sclerosis (MS). ...The presented data indicate that, apart from the cytostatic properties, mitoxantrone also exhibits side effects of its clinical applic
Mitoxantrone is an antineoplastic agent approved for clinical use in the secondary progressive phase of multiple sclerosis (MS). ...T
Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia.
Dunn CJ, Goa KL. Dunn CJ, et al. Drugs Aging. 1996 Aug;9(2):122-47. doi: 10.2165/00002512-199609020-00007. Drugs Aging. 1996. PMID: 8820798 Review.
Overall survival appears similar after treatment with regimens containing either mitoxantrone or daunorubicin in patients with ANLL, although there have been reports of trends towards increased survival rates with mitoxantrone. The incidence of cardiotoxicity appear …
Overall survival appears similar after treatment with regimens containing either mitoxantrone or daunorubicin in patients with ANLL, …
6,460 results